EP1869473A2 - Marqueur de polypeptide pour le diagnostic d'alzheimer - Google Patents

Marqueur de polypeptide pour le diagnostic d'alzheimer

Info

Publication number
EP1869473A2
EP1869473A2 EP06725566A EP06725566A EP1869473A2 EP 1869473 A2 EP1869473 A2 EP 1869473A2 EP 06725566 A EP06725566 A EP 06725566A EP 06725566 A EP06725566 A EP 06725566A EP 1869473 A2 EP1869473 A2 EP 1869473A2
Authority
EP
European Patent Office
Prior art keywords
mass
mol
alzheimer
markers
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06725566A
Other languages
German (de)
English (en)
Inventor
Harald Mischak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaiques Diagnostics and Therapeutics AG
Original Assignee
Mosaiques Diagnostics and Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG
Priority to EP06725566A priority Critical patent/EP1869473A2/fr
Publication of EP1869473A2 publication Critical patent/EP1869473A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Definitions

  • a worsening of the short-term memory as the first symptom is usually observed at the age of 60 to 70 years. Concentration and mental capacity diminish, speech disorders occur, fatigue increases. Often, symptoms of depression occur in the initial stages. There are also behavioral changes such as confusion, anxiety, restlessness and aggressiveness. They can no longer cope with everyday abilities like dressing, preparing food or shopping. Eventually they lose control of their body functions. In the final stage, patients often become silent, bedridden and completely dependent on the help of others.
  • Table 1 Polypeptide markers for the diagnosis of Alzheimer's and their molecular masses and migration times: No Mass Meal Time No Mass Meal Time No Mass Meal Time No Mass Meal Time
  • CE migration time can vary. Nevertheless, the order in which the polypeptide markers migrate is typically the same for each CE system used under the conditions indicated. To even out any differences in migration time, the system can be normalized using standards for which migration times are known. These standards may e.g. be the polypeptides given in the examples (see example point 3).
  • No. 1 or No. 50 but are not or only rarely present in subjects without Alzheimer's (control). Furthermore, there are polypeptide markers which are present in individuals without Alzheimer's disease, but which occur less frequently or not at all in individuals with Alzheimer's, for example polypeptide markers No. 43 or 44.
  • the sample measuring the presence or absence of the polypeptide marker (s) of the invention may be any sample recovered from the subject's body.
  • the sample is a sample having a polypeptide composition suitable for making statements about the condition of the individual (Alzheimer or not).
  • it may be blood, urine, synovial fluid, tissue fluid, body secretions, sweat, cerebrospinal fluid, lymph, intestinal, gastric, pancreatic, bile, tears, tissue, sperm, vaginal fluid, or a stool sample.
  • it is a liquid sample.
  • Blood samples may be taken by methods known in the art, for example from a vein, artery or capillary.
  • a blood sample is obtained by giving venous blood to an individual by means of a blood test Syringe eg is removed from the arm.
  • the term blood sample also includes samples obtained from blood by further purification and separation techniques known in the art, such as blood plasma or blood serum.
  • the presence or absence of a polypeptide marker in the sample can be determined by any method known in the art suitable for measuring polypeptide markers. Those skilled in such methods are known. In principle, the presence or absence of a polypeptide marker can be determined by direct methods such as mass spectrometry or indirect methods such as by ligands.
  • electrospray ionization (ESI) interfaces are most commonly used to measure ions from liquid samples, whereas the matrix assisted laser desorption / ionization (MALDI) technique is used to measure ions from sample crystallized with a matrix.
  • MALDI matrix assisted laser desorption / ionization
  • TOF time-of-flight
  • electrospray ionization (ESI) the molecules present in solution are sprayed under the influence of high voltage (eg 1-8 kV), forming charged droplets, which become smaller as the solvent evaporates.
  • high voltage eg 1-8 kV
  • Coulomb explosions lead to the formation of free ions, which can then be analyzed and detected.
  • CE-MS a CE-MS method which includes CE coupled online to an ESI-TOF-MS.
  • suitable solvents include acetonitrile, methanol and the like.
  • the solvents may be diluted with water and treated with a weak acid (eg, 0.1% formic acid) to protonate the analyte, preferably the polypeptides.
  • Capillary electrophoresis makes it possible to separate molecules according to their charge and size. Neutral particles migrate at the rate of electroosmotic flow upon application of a current, cations are accelerated to the cathode and anions are retarded.
  • the advantage of capillaries in electrophoresis is the favorable surface-to-volume ratio, which results in a good removal of the Joule heat arising during the current flow allows. This in turn allows the application of high voltages (usually up to 30 kV) and thus a high separation efficiency and short analysis times.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de diagnostic d'Alzheimer, comprenant l'étape de détermination de la présence, ou de l'absence, d'au moins un marqueur de polypeptide dans un échantillon, ledit marqueur de polypeptide étant choisi parmi les marqueurs 1-50 (marqueur de fréquence), ou la détermination de l'amplitude d'au moins un marqueur de polypeptide, choisi parmi les marqueurs 51-279 (marqueur d'amplitude) qui sont caractérisés par les valeurs suivantes pour les masses moléculaires et les temps de migration.
EP06725566A 2005-04-06 2006-04-05 Marqueur de polypeptide pour le diagnostic d'alzheimer Withdrawn EP1869473A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06725566A EP1869473A2 (fr) 2005-04-06 2006-04-05 Marqueur de polypeptide pour le diagnostic d'alzheimer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102705 2005-04-06
PCT/EP2006/061336 WO2006106115A2 (fr) 2005-04-06 2006-04-05 Marqueur de polypeptide pour le diagnostic d'alzheimer
EP06725566A EP1869473A2 (fr) 2005-04-06 2006-04-05 Marqueur de polypeptide pour le diagnostic d'alzheimer

Publications (1)

Publication Number Publication Date
EP1869473A2 true EP1869473A2 (fr) 2007-12-26

Family

ID=34939162

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06725566A Withdrawn EP1869473A2 (fr) 2005-04-06 2006-04-05 Marqueur de polypeptide pour le diagnostic d'alzheimer

Country Status (6)

Country Link
US (2) US20100036094A1 (fr)
EP (1) EP1869473A2 (fr)
JP (1) JP5147684B2 (fr)
AU (1) AU2006231597B2 (fr)
CA (1) CA2604033A1 (fr)
WO (1) WO2006106115A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017150680A1 (fr) * 2016-03-03 2017-09-08 東亞合成株式会社 Procédé de diagnostic de la maladie d'alzheimer en utilisant un peptide signal comme index

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10021737C2 (de) * 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
WO2004019043A2 (fr) * 2002-08-23 2004-03-04 Bayer Healthcare Ag Marqueurs biologiques permettant le diagnostic de la maladie d'alzheimer
DE10304106A1 (de) * 2003-01-31 2004-08-26 Mosaiques Diagnostics And Therapeutics Ag Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen
WO2005047484A2 (fr) * 2003-11-07 2005-05-26 Ciphergen Biosystems, Inc. Biomarqueurs pour la maladie d'alzheimer biomarkers for alzheimer's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006106115A3 *

Also Published As

Publication number Publication date
AU2006231597B2 (en) 2011-11-17
WO2006106115A3 (fr) 2006-11-23
CA2604033A1 (fr) 2006-10-12
US20150087554A1 (en) 2015-03-26
JP2008534973A (ja) 2008-08-28
US20100036094A1 (en) 2010-02-11
WO2006106115A8 (fr) 2007-11-08
AU2006231597A1 (en) 2006-10-12
JP5147684B2 (ja) 2013-02-20
WO2006106115A2 (fr) 2006-10-12

Similar Documents

Publication Publication Date Title
EP2338054A1 (fr) Carcinome à cellules rénales
WO2009115570A2 (fr) Procédé et marqueur permettant de diagnostiquer des maladies et dommages tubulaires rénaux
EP1757939A1 (fr) Marqueurs polypeptidiques pour la diagnose du cancer de la vessie
WO2008110593A2 (fr) Procédé et marqueurs pour le diagnostic de maladies rénales
WO2001084140A2 (fr) Procede et dispositif de determination qualitative et/ou quantitative d'un modele proteique et/ou peptidique d'un echantillon de liquide, preleve d'un corps humain ou animal
EP1955064A1 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
WO2006106129A2 (fr) Marqueurs polypeptidiques pour diagnostiquer le cancer de la prostate
WO2010079076A2 (fr) Maladie polykystique rénale autosomique dominante (adpkd)
DE10158180A1 (de) Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
EP2449385A1 (fr) Procédé et marqueur permettant de diagnostiquer une insuffisance rénale aiguë
WO2009050300A1 (fr) Procédé et marqueurs pour diagnostiquer le diabète sucré
EP2478377A2 (fr) Polypeptide marqueur pour le diagnostic et l'évaluation de maladies vasculaires
WO2009047280A2 (fr) Marqueur polypeptidique pour le diagnostic du cancer de la prostate
EP2810077A2 (fr) Marqueurs polypeptidiques pour le diagnostic et l'évaluation de l'insuffisance cardiaque
EP1896856A1 (fr) Marqueur polypeptidique servant a detecter le rejet d'un rein greffe a un stade precoce
EP1869473A2 (fr) Marqueur de polypeptide pour le diagnostic d'alzheimer
EP1784649B1 (fr) Marqueurs polypeptidiques pour le diagnostic de l'arteriosclerose
WO2012123527A1 (fr) Procédé et marqueurs de diagnostic de formes infracliniques et cliniques du rejet tubulo-interstitiel à médiation lymphocytaire t après une transplantation rénale
WO2007063089A2 (fr) Marqueur polypeptidique pour diagnostiquer et evaluer des maladies vasculaires
WO2013150132A2 (fr) Marqueurs polypeptidiques pour diagnostiquer et évaluer des accidents vasculaires cérébraux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071017

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111225

Country of ref document: HK

17Q First examination report despatched

Effective date: 20110208

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1111225

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151103